|
HanchorBio is a biotechnology company focused on the development of fusion protein biologics for the treatment of cancer and autoimmune diseases. Founded in 2020 by Dr. Scott Liu, the company utilizes its proprietary Fc-based Designer Biologics (FBDB™) technology platform to combine different targets for tumor therapy. Its pipeline includes multiple clinical-stage candidates, such as HCB101 and HCB301, which are in Phase 1 trials, and HCB303, a next-generation trispecific immunotherapy that has received IND clearance from the U.S. FDA. The company operates research centers in Taipei, Shanghai, and San Francisco, and serves markets in the United States, Taiwan, and Japan. HanchorBio has established partnerships with InSilicoTrials for AI-driven clinical development and engages in global collaborations with pharmaceutical leaders. The company holds over 100 patent applications globally and is listed on the Taipei Exchange. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Biotechnology | Homepage hanchorbio.com |
| Sector Healthcare | IR page hanchorbio.com/investors | |
|
Tags
oncology, autoimmune diseases, fusion proteins, immunotherapy, trispecific antibodies, fc-based designer biologics, clinical-stage pipeline, precision medicine, FBDB™, HCB101, HCB301, HCB303, InSilicoTrials
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 20.36B |
| P/E | -19.35 |
| P/BV | 15.36 |
| P/S | 65.21 |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -61.7% |
| ROI | -41.6% |
| ROIC | -41.4% |
| Profit margin | -88.6% |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | Yes |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | No |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -45.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | 312.223M | — | 0 |
| Net profit | -276.721M | -1.354B | -591.356M |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.